Selected traditional Chinese medicine interventions for post-stroke cerebral edema: a review integrating clinical evidence and mechanistic insights Authors: Junyue Huang, Yujia Jin, Yuping Chen, Mengsi Wang, Jian Wu Published: 2025 ABSTRACT BackgroundStroke is a leading cause of global death and disability. Post-stroke cerebral edema significantly worsens neurological outcomes. While conventional therapies face safety limitations, selected traditional Chinese medicine (TCM) interventions offer a potential alternative.Aim of the studyThis narrative review aims to comprehensively evaluate the efficacy and safety of TCM interventions for post-stroke cerebral edema and elucidate their potential mechanisms based on experimental evidence.Materials and methodsA systematic literature search was conducted in PubMed, Web of Science, and other databases using keywords related to stroke, cerebral edema, and TCM interventions. Studies were screened according to predefined inclusion criteria to ensure methodological rigor.ResultsClinical and preclinical studies indicate that TCM interventions can reduce cerebral edema volume, improve neurological outcomes, and exhibit good safety. These effects may be associated with modulation of ion homeostasis and aquaporins, neuroinflammatory inhibition, blood-brain barrier protection, oxidative stress reduction, and apoptosis suppression.ConclusionSelected TCM interventions show promise for post-stroke cerebral edema. Their clinical experience and mechanistic insights provide a valuable foundation for future research and drug development. Introduction Stroke, a primary global cause of death and severe long-term disability, is frequently complicated by cerebral edema—a potentially fatal condition affecting 10%–78% of ischemic and hemorrhagic stroke patients (Jiang et al., 2022). Each 1 mL increase in edema volume elevates the risk of adverse outcomes by 8.0%, exacerbating neurological deficits and mortality (Nawabi et al., 2019). BBB disruption is the most common etiology. Mannitol remains the first-line osmotic diuretic clinically, but carries significant limitations: high doses risk osmotic nephropathy, and rapid renal excretion can cause rebound intracranial hypertension (Cook et al., 2020; Papagianni et al., 2018). Decompressive craniectomy effectively reduces mortality but often leaves severe disability (Cooper et al., 2011). Consequently, clinical management of post-stroke cerebral edema remains challenging, driving increasing patient interest in TCM as an alternative or adjunctive therapy seeking improved efficacy and reduced adverse effects. In China, TCM has been used to treat stroke for over 2000 years, demonstrating notable efficacy and safety (Zhao et al., 2024). Recent research increasingly reveals its potential for post-stroke edema management. Numerous botanical drugs, formulas, and metabolites have been shown to reduce brain swelling, lower intracranial pressure, and improve neurological function in preclinical models and early clinical trials (Li X. et al., 2020; Widmann et al., 2018). Compared to mannitol or surgery, TCM therapies generally present lower risks of adverse reactions, making them particularly attractive for patients with comorbidities such as cardiac or renal insufficiency or diabetes (Lin et al., 2022). However, the clinical evidence and mechanisms underlying TCM require further elucidation. This article is presented as a narrative review that synthesizes current advances in the clinical efficacy and pharmacological mechanisms of TCM for post-stroke cerebral edema, aiming to guide clinical application and accelerate drug development. Methods In this review, we conducted a comprehensive literature search across six databases—Web of Science, PubMed, China National Knowledge Infrastructure (CNKI), VIP, Wanfang, and SinoMed—from inception to 23 July 2025 to evaluate the efficacy and safety of TCM for post-stroke cerebral edema. Key search terms included: “stroke,” “cerebral ischemia,” “intracerebral hemorrhage,” “edema,” “traditional Chinese medicine,” “herbal,” “TCM,” “formula,” “Clinical” and “patient.” Detailed search strategies for each database are listed in Supplementary. For clinical studies, the exclusion criteria were as follows: (a) case reports, reviews, commentaries, and animal studies; (b) studies involving non-ischemic or non-hemorrhagic stroke patients; (c) complementary and alternative therapies other than TCM, including acupuncture, moxibustion, cupping, massage, qigong, tai chi, yoga, and music therapy; and (d) studies without reported clinical outcomes. For preclinical studies, the exclusion criteria were as follows: (a) case reports, reviews, commentaries, and clinical studies; (b) studies using cell or animal models unrelated to stroke; (c) studies involving complementary and alternative therapies other than TCM, such as acupuncture, cupping, massage, and music therapy; and (d) studies lacking experimental outcome measures related to cerebral edema. Clinical evidence for selected TCM interventions in post-stroke cerebral edema Chinese botanical drug injections Chinese herbal injections are modern TCM preparations made from effective substances extracted from Chinese medicines (single botanical drugs or compound formulas), formulated as sterile solutions for intravenous or intramuscular injection to directly enter the systemic circulation. Xueshuantong Injection is a standardized TCM product extracted from Panax notoginseng (Burkill) F.H.Chen, with total saponins of P. notoginseng as its main metabolites. Panax notoginseng is widely used for promoting blood circulation and resolving stasis in the treatment of post-stroke cerebral edema. Pharmacological studies have shown that P. notoginseng can improve cerebral blood flow, protect vascular endothelial function, and scavenge free radicals (Pan et al., 2022). In clinical cases, Xueshuantong Injection has been shown to reduce the volume of cerebral edema and hematoma, improve hemodynamics, and decrease infarct volume (He et al., 2002). A systematic review of 21 clinical studies involving 1759 patients demonstrated that Xueshuantong exerts a protective effect on brain tissue during acute intracerebral hemorrhage and is more effective than the control group in reducing cerebral edema (Yu et al., 2011). A 160-patient clinical trial showed that compared with conventional treatment alone, Xueshuantong Injection combined with conventional treatment reduced edema volume and infarct size, enhanced anti-inflammatory responses, promoted neurological recovery, lowered disability rates, and improved quality of life and prognosis in patients with post-hemorrhagic stroke edema (Wang, 2018). Another clinical trial involving 115 patients reported that Xueshuantong Injection had a relatively safe, with an adverse reaction rate of 5.26% in the observation group and 3.45% in the control group. The main adverse reactions include gastrointestinal discomfort, skin rashes, fatigue, and other allergic reactions (Shang et al., 2022). The molecular biological mechanism of Xueshuantong Injection involves regulating the HIF1-α/VEGFA/VEGFR2 signaling pathway to promote vascular remodeling in the ischemic area after stroke, thereby reducing BBB leakage (Fang et al., 2023; Hatakeyama et al., 2020). Transcriptomic and proteomic analyses further revealed that Xueshuantong Injection significantly regulates the expression of related proteins and genes (VEGFA, VEGFR2, AKT, p-AKT, HIF-1α, GAPDH, EGFR, IL-6, HSP90AA1, NFKB1, PTEN) in middle cerebral artery occlusion (MCAO) model rats, suggesting that the HIF1-α/VEGFA/VEGFR2 signaling pathway is a potential key pathway for alleviating post-ischemic cerebral edema (Xiao et al., 2024). Shuxuetong Injection is a sterile aqueous solution extracted from animal-derived medicinal materials Hirudo nipponia Whitman (leech) and Pheretima aspergillum (E. Perrier) using modern biotechnology. Its main metabolites include hirudin-like polypeptides, earthworm fibrinolytic enzymes, and collagen hydrolysates (Sun et al., 2022). An 85-patient trial in intracerebral hemorrhage (ICH) patients showed that Shuxuetong Injection improved cerebral edema severity, reduced hematoma volume, enhanced NIHSS scores, and promoted neurological recovery in post-hemorrhagic cerebral edema, with no significant adverse effects reported (Yao, 2012). In addition, another clinical trial involving 120 patients with intracerebral hemorrhage showed that compared with conventional treatment, Shuxuetong Injection combined with conventional treatment was more effective in reducing the volume of cerebral edema and hematoma (Liang and Yang, 2012). Mechanistic insights from preclinical models propose that Shuxuetong may alleviate cerebral edema by inhibiting pyroptosis, a pro-inflammatory form of cell death, potentially via the CD44/NLRP3/GSDMD signaling pathway (Shang et al., 2025). Commercial Chinese polyherbal preparation (CCPP) Commercial Chinese polyherbal preparation are standardized TCM preparations produced in batches with fixed formulas and processes, using Chinese medicinal materials as raw materials, and having specific dosage forms and efficacy. Naoxueshu Oral Liquid, a clinically utilized Chinese CCPP for qi-supplementing, blood-activating, stasis-resolving, and fluid-promoting effects, contains components including Astragalus mongholicus Bunge, H. nipponia Whitman, Acorus tatarinowii Schott, Achyranthes bidentata Blume, Paeonia suffruticosa Andr., Rheum officinale Baill., and Ligusticum chuanxiong Hort (Li P. et al., 2024). Modern studies on its active substances have identified over 100 distinct metabolites in the formula, which exert synergistic multi-target effects to facilitate edema absorption and neurological recovery after stroke (Li R. et al., 2024). A network meta-analysis of 19 studies (n = 2,335 patients) demonstrated that Naoxueshu combined with Western medicines (nimodipine, nifedipine, edaravone) significantly reduced cerebral edema volume and hematoma size, improved NIHSS scores, and exerted anti-inflammatory effects compared to Western medicines alone (Mei et al., 2022). A 220-patient trial showed that Naoxueshu plus conventional treatment Moderately decreased edema and hematoma volume while improving neurological function scores versus conventional treatment alone (Song et al., 2022). In addition, A 120-patient study in post-stroke rehabilitation reported that 7-day Naoxueshu treatment reduced cerebral hematoma and edema volume without affecting fibrinogen levels or causing adverse effects (Song et al., 2021). Experimental research suggests potential mechanisms for these benefits. Studies in rat models of intracerebral hemorrhage indicate that Naoxueshu may reduce BBB permeability and alleviate edema, potentially through modulating astrocyte function, promoting the expression of the tight junction protein ZO-1, and inhibiting AQP4 protein (Wang et al., 2019). Angong Niuhuang Pill is a commercially available Chinese CCPP. This pill is composed of 11 medicinal components: Bos taurus domesticus Gmelin, Moschus moschiferus Linnaeus, Bubalus bubalis Linnaeus (horn, concentrated powder), Pinctada martensii (Dunker), Cinnabaris, Realgar, Coptis chinensis Franch., Scutellaria baicalensis Georgi, Gardenia jasminoides Ellis, Curcuma aromatica Salisb., and Dryobalanops aromatica Gaertn. f (Bai et al., 2024). An 80-patient trial in acute cerebral infarction (ACI) demonstrated that Angong Niuhuang Pill combined with conventional treatment significantly reduced edema volume and improved NIHSS and GCS scores compared to conventional treatment alone (Feng and Yang, 2015). In addition, A larger 122-patient trial in ACI reported that the pill restored midline shift, Significantly decreased edema volume, modulated vascular tone, and enhanced neurological function and quality of life (Zhang and Chen, 2016). Notably, realgar and cinnabar—key components—contributed to neuroprotective effects without inducing hepatotoxicity or nephrotoxicity in transient ischemic brain injury models (Tsoi et al., 2019a). Systems biology approaches have shown that Angong Niuhuang Pill can effectively improve cerebrovascular edema in mice, which may be associated with the inhibition of VE-cadherin expression and the upregulation of CAV-1 phosphorylation and AQP4 expression in mouse brain tissue (Liu et al., 2024). Another study suggested a potential mechanism involving the prevention of MMP-9 activation via scavenging peroxynitrite, thereby protecting microvascular integrity (Chen H. et al., 2022). Chinese medicinal formulae Chinese Medicinal Formulae represent systematic combinations of multiple herbs—often guided by principles such as “monarch, minister, assistant, and guide”—with the goal of producing synergistic therapeutic effects. Buyang Huanwu Decoction, derived from Yilin Gaicuo by Wang Qingren in the Qing Dynasty, is a classic formula for treating post-stroke sequelae, composed of seven medicinal components: Astragalus membranaceus (Fisch.) Bunge, Angelica sinensis (Oliv.) Diels, Paeonia lactiflora Pall., L. chuanxiong Hort., P. aspergillum (E. Perrier), Prunus persica (L.) Batsch, and Carthamus tinctorius L. Its standardized extract contains core metabolites such as astragaloside IV, ferulic acid, paeoniflorin, and hydroxysafflor yellow A (Pan et al., 2025). A 104-patient trial post-intracerebral hemorrhage surgery showed that Buyang Huanwu Decoction combined with ultra-early urokinase significantly reduced cerebral edema probability, increased overall response rates, and demonstrated a favorable safety profile compared to urokinase alone (Hou et al., 2022). Another 52-patient study in ACI reported that Buyang Huanwu Decoction can reduce the content of β2-MG in CSF of patients with acute cerebral infarction, alleviate cerebral edema, and has reliable clinical efficacy (Jia and Liu, 2007; Xiao et al., 2021). Separately, research suggests it may prevent cerebral edema after ischemia by inhibiting the HIF-1α/VEGF pathway and stabilizing β-ENaC ion channels in the brain. Preclinical studies have proposed multiple potential mechanisms. In rat models, its effects have been associated with the inhibition of the NIK-mediated non-canonical NF-κB pathway to reduce inflammatory responses after intracerebral hemorrhage (Xiao et al., 2021). Separately, research suggests it may prevent cerebral edema after ischemia by inhibiting the HIF-1α/VEGF pathway and stabilizing β-ENaC ion channels in the brain (Chen et al., 2019). Clinical reports on Chinese Botanical Drug Injections, commercial Chinese polyherbal preparation and TCM Formulas are summarized in Table 1. TABLE 1Clinical reports related to the treatment of post-stroke cerebral edema with selected TCM interventions.DiseasePrescriptionSample sizeTreatment durationExperimental groupControl groupEdema volume (experimental/control group)Outcome indicatorsAdverse reactionsAuthor(s) and yearCerebral hemorrhageXueshuantong injection16014 daysRoutine treatment + Xueshuantong Injection 4 mL ivgtt qdRoutine treatment75.86%hs-CRP ↓, MMP-9 ↓, MBP ↓, NSE ↓, S100B protein ↓N Wang (2018) Shuxuetong injection12014 daysRoutine treatment + Shuxuetong Injection 4 mL ivgtt qdRoutine treatment48.27%hematoma volume ↓, fibrinogen ↓N Liang and Yang (2012) Danshen injection12014 daysRoutine treatment + Nimodipine + Danshen Injection 16 mL ivgtt tidRoutine treatment + Nimodipine59.54%ESS ↑N Zeng (2015) Erigeron breviscapus injection10014 daysRoutine treatment + Edaravone + Erigeron Breviscapus Injection 40 mL ivgtt qdRoutine treatment + Edaravone78.47%cerebral hematoma volume ↓, NIHSS ↑, IL-18 ↓, HSP47 ↓, CD163 ↓, S100β ↓N Wei et al. (2024) Naoxueshu oral liquid1207 daysRoutine treatment + Naoxueshu Oral Liquid 10 mL po tidRoutine treatment86.2%hematoma volume ↓, NIHSS ↓N Song et al. (2022) Jianshen lishui granule10014 daysRoutine treatment + Furosemide + Jianshen Lishui Granule 91g po tidRoutine treatment + Furosemide49.35%hematoma volume ↓, NIHSS ↓, hs-CRP ↓, S-100β protein ↓, IL-1β ↓Y Tan et al. (2021) Longhu xingnao granule2514 daysTorasemide + Mannitol + Longhu Xingnao Granule 10g po bidTorasemide + Mannitol70.39%hematoma volume ↓, NIHSS ↓, ADL ↑N Yu et al. (2018) Huoxue tongli decoction17021 daysRoutine treatment + Huoxue Tongli Decoction 100 mL po bidRoutine treatment61.90%hematoma absorption rate ↑N Zhao et al. (2010) Huoxue ditan decoction10614 daysRoutine treatment + Hyperbaric oxygen + Huoxue Ditan Decoction 100 mL po bidRoutine treatment + Hyperbaric oxygen76.42%NIHSS ↑, ET ↓, NO ↓, IL-1 ↓N Gao et al. (2020) Changpu yujin decoction13030 daysRoutine treatment + Changpu Yujin Decoction 50 mL Nasogastric Gavage q4hRoutine treatment83.69%hs-CRP ↓, NSE ↓, FIB ↓N Fu et al. (2019) Sanyu tongluo decoction12020 daysRoutine treatment + Sanyu Tongluo Decoction 100 mL po qdRoutine treatment65.45%cerebral hematoma ↓, NIHSS ↓, BI ↑, IL-6 ↓, IL-4 ↓, BDNF ↓, VEGF ↓N Yu et al. (2023) Liangxue sanyu decoction7214 daysNimodipine + Liangxue Sanyu Decoction 95g po bidRoutine treatment + Nimodipine81.24%NIHSS ↓, BI ↑N Zhong et al. (2019) Lingjiao gouteng decoction1023 monthsRoutine treatment + Lingjiao Gouteng Decoction 90g po bidRoutine treatment73.83%hematoma volume ↓, NIHSS ↓, PRO ↓, Barthel ↑, modified Rankin ↓N Jiao and Xu (2015) Cerebral ischemiaAngong niuhuang pill12214 daysRoutine treatment + Angong Niuhuang Pill 3g po qdRoutine treatment60.22%recovery of midline shift ↑, GCS ↑, NIHSS ↓, ADMA ↓, NO ↑N Zhang and Chen (2016) Buyang huanwu decoction5214 daysRoutine treatment + Buyang Huanwu Decoction 100 mL po bidRoutine treatment66.88%β2-MG ↓N Jia and Liu (2007) Xiaoxuming decoction9014 daysRoutine treatment + Xiaoxuming Decoction 100 mL po bidRoutine treatment71.25%S-100β ↓, NSE ↓, MBP ↓, NIHSS ↓N Zhao et al. (2023) Xinglou chengqi decoction507 daysRoutine treatment + Xinglou Chengqi Decoction 62g po bidRoutine treatment73.33%cerebral hematoma volume ↓, NIHSS ↑N Fan (2019) a Routine treatment: Includes antiplatelet therapy, antihypertensive therapy, lipid regulation, improvement of circulation and neuroprotection. The specific components of routine treatment may vary slightly among different studies. Clinical reports related to the treatment of post-stroke cerebral edema with selected TCM interventions. Routine treatment: Includes antiplatelet therapy, antihypertensive therapy, lipid regulation, improvement of circulation and neuroprotection. The specific components of routine treatment may vary slightly among different studies. Adverse reactions In recent years, With the expanding clinical application of TCM, reports of adverse reactions have correspondingly increased. The most common reactions involve the skin, digestive, and respiratory systems, manifesting as pruritus, rashes, flatulence, fatigue, vomiting, headache, and dizziness. Primary management strategies include drug discontinuation and symptomatic treatment (Lai et al., 2013). A meta-analysis of 40 RCTs (n = 3,868) showed no significant difference in adverse reaction rates between Xueshuantong plus conventional therapy (12.5%) and conventional therapy alone (11.4%) (Lyu et al., 2020). Another systematic review of Naoxueshu Injection for ICH (n = 1,602) reported significantly reduced cerebral edema in the treatment group versus controls, with no abnormalities in safety parameters (blood/coagulation profiles, liver/kidney function) and no mortality difference (Wang et al., 2025). Animal toxicology studies demonstrated that rats administered Angong Niuhuang Pill at human-equivalent doses exhibited no mercury accumulation in blood, liver, or kidneys within 7–14 days; although arsenic levels increased in the liver and blood (not kidneys), short-term use (≤7 days) remained safe (Tsoi et al., 2019b). However, most of the included clinical studies did not use standardized reporting protocols for adverse events, and some studies did not report adverse reactions at all, which may limit the comparability and interpretation of safety data across studies. In summary, Selected TCM interventions exhibits an acceptable safety profile in clinical practice. Future efforts should prioritize standardized adverse event reporting, rigorous safety evaluations, and long-term follow-up in large-scale trials to further strengthen the reliability of safety data. Pharmacological mechanisms of selected TCM interventions in post-stroke cerebral edema The pathological mechanisms of cerebral edema after stroke differ essentially between intracerebral hemorrhage and cerebral ischemia. Intracerebral hemorrhage drives progressive vasogenic edema through thrombin-mediated endothelial injury combined with iron-catalyzed Fenton reactions from hemoglobin degradation, which disrupt BBB integrity. Cerebral ischemia initially induces cytotoxic edema due to sodium-potassium pump dysfunction caused by energy failure, and then transforms into vasogenic edema during reperfusion as reactive oxygen species (ROS) bursts activate matrix metalloproteinases (MMPs) to degrade tight junction proteins. The treatment of cytotoxic edema primarily involves regulating fluid metabolism and ion homeostasis, while the key to treating vasogenic edema lies in protecting and repairing the BBB (Wang et al., 2024a). The treatment of both types of edema requires inhibiting the neuroinflammatory cascade to block the transformation of cytotoxic edema to vasogenic edema, ultimately achieving edema resolution (Zheng et al., 2023). Preclinical evidence suggests that selected TCM interventions may ameliorate cerebral edema by targeting interconnected pathological processes. Evidence for their potential mechanisms of action comes primarily from animal and cell-based models, and points to several key processes: the regulation of ion homeostasis and aquaporins, inhibition of neuroinflammatory cascades, protection and repair of the BBB, and the mitigation of oxidative stress and apoptosis. These potential mechanisms are illustrated in Figure 1. Basic research on TCM monomers and Chinese Herbal Formulas are presented in Tables 2, 3, respectively. It is important to note that this evidence currently constitutes a framework of hypotheses that must be rigorously tested. The critical next steps for the field will involve establishing causal validation of these mechanisms in humans and identifying the principal active constituents within the complex formulas. Building on this foundation, the following sections will elaborate on each of these mechanisms. Pharmacological mechanisms of selected traditional Chinese medicine interventions for post-stroke cerebral edema. TABLE 2Statistics of basic experimental studies on the treatment of post-stroke cerebral edema with Chinese herbal metabolite.EffectSourceActive componentStructureAnimal/cellsTreatmentTargetsReferencesRegulating fluid metabolism and ion homeostasis Rheum palmatum L.Emodin x3B1 SD ratPrimary rat cortical astrocytes In vivo: MCAO rats received intravenous emodin (15 mg/kg) at 8 and 12 h post-reperfusion, with outcomes measured at 24 h. In vitro: Cells were pre-treated with liposomal emodin for 24 h prior to OGD/R.Brain water content↓, AQP4 ↓, ZO-1↑, Claudin 1↑, TNF-α↓, IL-1β↓, IL-6↓ Chen et al. (2024) Cornus officinalis Sieb. et ZuccCornel Iridoid glycoside x3B1 SD rat In vivo: MCAO/R rats were pre-treated with CIG (15 and 30 mg/kg, i.g.) for 3 days and once at 2 h before ischemia, with outcomes measured at 24 h post-reperfusion.Brain water content↓, AQP4 ↓, pyknotic nucleus ↓, vacuole degeneration↓ Wang et al. (2020) Dioscorea zingiberensis C.H.WrightTotal steroid saponins x3B1 SD rat In vivo: MCAO/R rats were pre-treated with TSSN (30, 10, and 3 mg/kg, i.g.) or Nimodipine (20 mg/kg, i.g.) once daily for 7 days before ischemia, with outcomes measured at 24 h post-reperfusion.Brain water content↓, AQP-4↓, neurological deficit scores↑, cerebral infarct size↓, CAT↑, SOD↑, NO↓, MDA↓, iNOS↓, NF-κB↓, ERK 1/2↓ Zhang et al. (2014) Gastrodia elata BlumePhenolic glucoside gastrodin x3B1 SD rat, rat hippocampal neurons In vivo: MCAO rats received intraperitoneal gastrodin (100 and 50 mg/kg) at the onset of ischemia, with outcomes measured at 24 h post-reperfusion. In vitro: Cultured hippocampal neurons were treated with gastrodin (30 and 15 μg/mL) during OGD/glutamate exposure and the subsequent 24-h period.Brain water content↓, cerebral infarct size↓, Ca2+↓, NO↓, glutamic acid↓ Zeng et al. (2006).Protecting and repairing the BBB Citrus paradisi Macfadyen Citrus aurantium L.Naringenin x3B1 C57BL/6J mice In vivo: MCAO mice received intraperitoneal NAR (10 mg/kg) once daily for 6 days immediately after reperfusion, with outcomes measured at 7 days.Cerebral infarct size↓, ZO-1↑, Occludin↑, Claudin-5↑, IL-1β↓, IL-6↓, TNF-α↓, β-catenin↑, p-GSK-3β (ser-9)↑ Yang et al. (2024) Curcuma longa L.Curcumin x3B1 RBMEC In vitro: RBMECs were treated with curcumin (20 μM) during OGD for 24 h.Brain water content↓, Occludin↑, ZO-1↑, HO-1↓ Wang et al. (2013) Scutellaria baicalensis GeorgiBaicalin x3B1 BMVECs In vitro: BMVECs were treated with baicalin (5, 10, 20 μg/mL) during OGD for 24 h.brain water content↓, Oclaudin-5↑, ZO-1↑, PKC↓ Zhu et al. (2012) Crocus sativus L.Crocin x3B1 C57BL/6J mice In vivo: BCCAO mice received crocin (20, 10, 5 mg/kg) intragastrically once daily for 21 days before I/R, with outcomes measured at 24 h post-reperfusion.Brain water content↓, NO↓, MDA↓, SOD↑, GSH-px↑, MMP-9↓, ERK1/2 phosphorylation↓ Zheng et al. (2007) Coffea arabica L. Cichorium intybus L.Dihydrocaffeic acid x3B1 SD rat In vivo: tMCAo rats received intraperitoneal DHCA (3, 10, 30 mg/kg) at 0 and 2 h after onset of ischemia, with outcomes measured at 24 h after ischemia.Brain water content↓, cerebral infarct size↓, EB extravasation↓, MMP-2↓, MMP-9↓ Lee et al. (2015) Panax ginseng C. A. Mey.Ginsenoside Rd x3B1 SD rat In vivo: MCAO rats received intraperitoneal Ginsenoside Rd (30 mg/kg) 1 h before ischemia, with outcomes measured at 24 h after MCAO.Brain water content↓, NF-κB↓, MMP-9↓ Zhang et al. (2020) Curcuma longa L.Tetrahydrocurcumin x3B1 CBS heterozygous knockout mice In vivo: MCAO mice received intraperitoneal THC (25 mg/kg in 0.1% DMSO) daily for 3 days starting at 30 min post-ischemia, with outcomes measured at 72 h post-reperfusion.Brain water content↓, Hcy ↓, MMP-9 ↓, LC3-II↓, DRAM↓ Tyagi et al. (2012).Inhibiting neuroinflammatory cascades Rehmannia glutinosa Libosch, Ligustrum lucidum Ait., Plantago lanceolata L., Verbena officinalis L.Verbascoside x3B1 C57BL/6J mice In vivo: ICH mice received intraperitoneal VB (15 or 30 mg/kg) 15 min post-ICH, with outcomes measured at 24, 48, and 72 h.Brain water content↓, TLR4↓, NF-κB↓, TNF-α↓, IL-1β↓, IL-6↓ Lai et al. (2019) Ginkgo biloba L.Ginkgolide C x3B1 SD rat In vivo: MCAO/R rats received intraperitoneal GC (8, 16, or 32 mg/kg) daily for 3 days starting at reperfusion, with outcomes measured at 72 h post-reperfusion.Brain water content↓, cerebral infarct size↓, MPO↑, ICAM-1↓, VCAM-1↓, iNOS ↓, CD40↓, TNF-α↓, IL-1β↓, IL-6↓ Li et al. (2023) Vitis vinifera L., Pinus pinaster Aiton, Nelumbo nucifera GaertnProcyanidins x3B1 SD ratBV-2cells In vivo: MCAO/R rats received intragastric procyanidins (20, 40, or 80 mg/kg) 1 h before ischemia, with outcomes measured at 24 h post-reperfusion. In vitro: BV2 cells were pre-treated with procyanidins (10 μM) for 2 h prior to OGD/R.Brain water content↓, cerebral infarct size↓, TLR4↓,p38↓, NF-κB↓, NLRP3↓ Yang et al. (2020) Ginkgo biloba L.Ginkgo diterpene lactones x3B1 SD ratCortical astrocytes In vivo: MCAO/R rats received intravenous GDL (1.25 mg/kg) at 1 h after reperfusion, twice daily for 3 days, with outcomes measured at 72 h after MCAO. In vitro: Astrocytes were pre-treated with GDL (12.5, 25, 50 μg/mL) for 24 h prior to OGD/R.Brain water content↓, cerebral infarct size↓, IL-1β↓, TNF-α↓, TLR4 ↓, NF-κB, LDH↓ Li Z. et al. (2020) Paeonia suffruticosa Andr., Cynanchum paniculatum (Bunge) Kitagawapaeonol x3B1 SD rat In vivo: MCAO rats received intraperitoneal paeonol (25 mg/kg) at the onset of ischemia and then once daily, with outcomes measured at 72 h and 28 days after reperfusion.Brain water content↓, cerebral infarct size↓, astrocytes↓, Iba-1-positive microglia↓ Zhao et al. (2018) Ferula sinkiangensis K. M. ShenKellerin x3B1 SD ratBV2 and SH-SY5Y cells In vivo: MCAO rats received intragastric kellerin (3.5, 7.0, 14.0 mg/kg) at the onset of reperfusion, with outcomes measured at 24 h after reperfusion. In vitro: Cells were pre-treated with kellerin (1, 5, 10 µM) for 2 h prior to LPS stimulation.Brain water content↓, cerebral infarct size↓, NO↓, iNOS↓, NF-κB↓, ROS↓, NADPH↓ Mi et al. (2021) Artemisia annua L.Artemisinin x3B1 C57BL/6J mice In vivo: ICH mice received intraperitoneal artemisinin (5 mg/kg) once daily, with outcomes measured at 24 h and 72 h after ICH.Brain water content↓, L1↓, ROS↓, GSH↓, SOD↓, IL-1β↓, IL-6↓, TNF-α↓ Wang et al. (2022a) Anti-oxidative stressOlea europaea L., Ligustrum lucidum Ait.oleanolic acid x3B1 Primary cultured cortical neurons In vitro: Cultured rat cortical neurons were pre-treated with Aralia cordata extract (5-20 μg/mL) or Oleanolic Acid (0.5-5 µM) for 15 min prior to H2O2 exposure.Brain water content↓, cerebral infarct size↓, Ca2+↓, ROS↓ Cho et al. (2009) Rehmannia glutinosa (Gaertn.) DC., Picrorhiza scrophulariiflora Pennell, Scrophularia ningpoensis Hemsl.Catalpol x3B1 SD rat In vivo: MCAO rats received Catalpol (2.5, 5, 10 mg/kg, intranasal) for 3 days after modeling, with outcomes measured at 72 h post-reperfusion.Brain water content↓, cerebral infarct size↓, SOD↓, MDA↓, Bcl-2↓, Bax↑, Nrf2↑, HO-1↑ Wang et al. (2022b) Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) HsiaoAstragaloside IV x3B1 SD rat In vivo: MCAO rats received Astragaloside IV (20 mg/kg, i.p.) at 30 min after occlusion, with outcomes measured at 72 h post-reperfusion.Brain water content↓, cerebral infarct size↓, ROS↓, MDA↓, GSH↓, TNF-α↓, NF-κB↓, IL-6↓, IL-1β↓, GPX4↓, SLC7A11↓, Nrf2↓,HO-1↓ Zhang et al. (2023) Anoectochilus roxburghii (Wall.) LindlKinsenoside x3B1 C57BL/6J mice bEnd.3 cell In vivo: MCAO mice received Kinsenoside (1, 5, 10 μg, intracerebroventricular) immediately upon reperfusion after 1 h of ischemia, with outcomes measured at 72 h post-reperfusion. In vitro: Cells were treated with Kinsenoside (10, 15, 20 μg/mL) during the 14-h reoxygenation phase following OGD/R.Brain water content↓, cerebral infarct size↓, ROS↓, SOD↑, Nrf2↓, HO-1↓, Occludin↑, claudin-5↑, ZO-1 ↑ Qiao et al. (2023) Glycine max (L.) Merr.Soy Isoflavones x3B1 ICR ratsPC12 cells In vivo: BCCAO rats received oral soy isoflavones (100 mg/kg) for 5 days prior to ischemia-reperfusion, with outcomes measured at 24 h post-reperfusion. In vitro: PC12 cells were treated with soy isoflavones (140, 280, 560 μg/mL) during reoxygenation after OGD/R for 24 h.Brain water content↓, cerebral infarct size↓, SOD↑, GSH↑, CAT ↑, MDA↓, LDH ↓, Nrf2↑, HO-1↑, NQO1↑, Keap1 ↓ Xue et al. (2025) Apium graveolens L. var. dulce DC., Matricaria recutita L., Petroselinum crispum Apigenin x3B1 SD rat In vivo: pMCAO rats were pre-treated with apigenin (30, 60, 120 mg/kg) via gavage for 7 days before ischemia, with outcomes measured at 24 h after pMCAO.Brain water content↓,cerebral infarct size↓, SOD↑, GSH↑, ROS↑, MDA↓, caspase↓, Cyt c↓ Ping et al. (2024) Carthamus tinctorius L.Hydroxysafflor yellow A x3B1 SD rat In vivo: MCAO rats received intravenous HSYA (2.5, 5, 10 mg/kg) at 1 h after ischemia onset, with outcomes measured at 24 h after ischemia.Brain water content↓, cerebral infarct size↓, iNOS↓, NO↓ Sun et al. (2013) Anti-apoptosis Schisandra chinensis (Turcz.) Baill., Schisandra sphenanthera Rehd. et Wils.Schisandrin B x3B1 SD rat In vivo: MCAO rats received intraperitoneal Sch B (50, 100 mg/kg) at 2 and 12 h after ischemia onset, with outcomes measured at 24 and 72 h after MCAO.Brain water content↓, cerebral infarct size↓, Bax/Bcl-2↓, caspase-3↓, IL-18↓, MDA↓, NO↓, SOD↑ Hong et al. (2023) Ginkgo biloba L.Ginkgolide B x3B1 SD ratPC12 cells In vivo: MCAO/R rats received oral administration of XQ-1H (7.8, 15.6, 31.2 mg/kg) starting at 4 h post-reperfusion and then every 8 h for 3 days, with outcomes measured at 72 h In vitro: Cells were treated with XQ-1H (1, 3, 10, 50, 100 μM) for 24 h during reoxygenation after OGD/R.Brain water content↓, cerebral infarct size↓, bcl-2↑, bax↓ Khadankhuu et al. (2021) Statistics of basic experimental studies on the treatment of post-stroke cerebral edema with Chinese herbal metabolite. TABLE 3Statistics of basic experimental studies on the treatment of post-stroke cerebral edema with Chinese herbal formulae.EffectFormulasComplete compositionAnimal/CellTreatmentTargetsReferencesRegulating fluid metabolism and ion homeostasisTongxinluo Panax ginseng C. A. Mey., Hirudo nipponica Whitman, Buthus martensii Karsch, Paeonia lactiflora Pall., Cryptotympana pustulata Fabricius, Eupolyphaga sinensis Walker, Scolopendra subspinipes mutilans L. Koch, Santalum album L., Dalbergia odorifera T. Chen, Boswellia carterii Birdw., Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chow, Dryobalanops aromatica Gaertn. f. (for natural Borneol)SD mice In vivo: MCAO/R rats received oral administration of Tongxinluo (1.6 g/kg/day, twice daily) for 3 days before and after ischemia, with outcomes measured at 24 h and 72 h post-reperfusion.Brain water content↓, AQP4↓, HMGB1↓, TLR4↓, NF-κB↓ Cai et al. (2016) Goreisan Polyporus umbellatus (Pers.) Fries, Poria cocos (Schw.) Wolf, Atractylodes macrocephala Koidz., Alisma orientale (Sam.) Juzep., Cinnamomum cassia PreslddY mice In vivo: MCAO mice received oral administration of Goreisan (500 mg/kg, twice daily) for 5 days before ischemia, with outcomes measured at 24 h post-reperfusion.Brain water content↓, AQP4↓ Nakano et al. (2018) Protecting and repairing the BBBYiQiFuMai powder injection Panax ginseng C. A. Mey., Ophiopogon japonicus (L. f.) Ker-Gawl. Schisandra chinensis (Turcz.) Baill.C57BL/6J mice In vivo: MCAO mice received intraperitoneal administration of YiQiFuMai powder injection (0.336, 0.671, and 1.342 g/kg) at 1 h post-reperfusion, with outcomes measured at 24 h.Brain water content↓, cerebral infarct size↓, leakage of EB↓, ZO-1↑, occludin↑ Cao et al. (2016) Tongxinluo Panax ginseng C. A. Mey., Hirudo nipponica Whitman, Buthus martensii Karsch, Paeonia lactiflora Pall., Cryptotympana pustulata Fabricius, Eupolyphaga sinensis Walker, Scolopendra subspinipes mutilans L. Koch, Santalum album L., Dalbergia odorifera T. Chen, Boswellia carterii Birdw., Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chow, Dryobalanops aromatica Gaertn. f.CD1 male mice In vivo: tMCAO mice received oral administration of Tongxinluo (1 g/kg/day) in different regimens (pre-treatment for 7 days; pre-post treatment for 7 days before and 14 days after ischemia), with outcomes measured at multiple time points (1, 3, 7, 14 days) post-reperfusion.Brain water content↓, cerebral infarct size↓, IL-6↓, IL-1β↓, TNF-α↓, MPO↓, BBB damage↓ Liu et al. (2013) Cerebralcare Granule Astragalus membranaceus (Fisch.) Bge. Hirudo nipponica Whitman, Acorus tatarinowii Schott, Achyranthes bidentata Blume, Paeonia suffruticosa Andr., Rheum palmatum L., Ligusticum chuanxiong Hort.SD mice In vivo: MCAO rats received oral Cerebralcare Granule (0.4 g/kg or 0.8 g/kg) at 3 h post-reperfusion and then once daily for 6 days, with outcomes measured at 3 h and 6 days post-reperfusion.Brain water content↓, cerebral infarct size↓, claudin-5↑, JAM-1↑, occludin↑, zonula↑,occluden-1↑, caveolin-1↓ Huang et al. (2012) Houshiheisan Chrysanthemum morifolium Ramat., Atractylodes macrocephala Koidz., Asarum sieboldii Miq., Poria cocos (Schw.) Wolf, Ostrea gigas Thunberg, Platycodon grandiflorum (Jacq.) A. DC., Saposhnikovia divaricata (Turcz.) Schischk., Panax ginseng C. A. Mey., Alum, Scutellaria baicalensis Georgi, Angelica sinensis (Oliv.) Diels, Zingiber officinale Rosc., Ligusticum chuanxiong Hort., Cinnamomum cassia Presl.SD miceIm-HUVECs In vivo: pMCAO rats received intragastric administration of Houshiheisan (5.25 g/kg or 10.5 g/kg) at 6 h post-modeling and then once daily for 7 consecutive days, with outcomes measured at 7 days. In vitro: Cells were treated with HSHS medicated serum (2.5%, 5%, 10%, or 20%) for 24 h prior to and during OGD for 6 h, with outcomes measured post-OGD.Blood vessel edema↓, SDF-1α↓, CXCR4↓, HIF-1α↑, VEGFA↑, Ang-1↑, Ang-2↓ Xiang et al. (2019) Inhibiting neuroinflammatory cascadesZhongfeng Xingnao prescription Panax ginseng C. A. Mey., Panax notoginseng (Burk.) F. H. Chen, Ligusticum chuanxiong Hort., Rheum palmatum L.SD mice In vivo: ICH rats received intragastric administration of Zhongfeng Xingnao Prescription (4.5, 9, or 18 mL/kg) starting at 24 h post-modeling and then once daily for 5 consecutive days, with outcomes measured at 5 days.Edema and vacuole conditions around the hematoma↓, p-NF-κB p65↓, NLRP3↓, Caspase1↓, IL-1β↓, TNF-α↓ Yu et al. (2025) QiShenYiQi Astragalus membranaceus (Fisch.) Bge., Salvia miltiorrhiza Bunge, Panax notoginseng (Burk.) F. H. Chen, Dalbergia odorifera T. Chen.ICR mice In vivo: MCAO mice were pretreated with QSYQ (56.9, 113.8, 227.5 mg/kg) orally for 7 days before surgery (1 h ischemia/24 h reperfusion), with outcomes measured at 24 h.Brain water content↓, cerebral infarct size↓, IFNG-γ↓, IL-1β↓,IL-6↓, TNF-α↓, NF-κB p65↓, TGF-β1↓, TLR-4↓ Wang et al. (2020) Anti-apoptosisDanhong injection Salvia miltiorrhiza Bunge, Carthamus tinctorius L.SD miceMCAO rats received intravenous DHI (0.5, 1.0, 2.0 mL/kg) once daily for 7 days post-reperfusion, with outcomes measured at day 7.Brain water content↓, cerebral infarct size↓, MDA↓, SOD↑, T-AOC↑, NAD ↓, pyruvate↓, HIF1α↓, PDK1↓, pPDHA1↓ Zeng et al. (2021) a The medicinal compositions of all formulas listed in this table are directly extracted and summarized from the original research articles cited in the “Reference” column. Statistics of basic experimental studies on the treatment of post-stroke cerebral edema with Chinese herbal formulae. The medicinal compositions of all formulas listed in this table are directly extracted and summarized from the original research articles cited in the “Reference” column. Regulating fluid metabolism and ion homeostasis Disorders of fluid metabolism and ion homeostasis are the core pathological hubs of post-stroke cerebral edema, presenting distinct processes in cerebral ischemia and intracerebral hemorrhage. Cerebral ischemia initially causes sodium and water retention in neurons due to Na+/K+-ATPase dysfunction from energy failure (Sylvain et al., 2021), forming cytotoxic edema, accompanied by abnormal polarity distribution of astrocyte AQP4 aquaporins, which exacerbates swelling (Kitchen et al., 2020; Markou et al., 2022). Intracerebral hemorrhage directly impairs microcirculation due to mechanical compression by hematoma, combined with thrombin activation and free iron from hemoglobin degradation, which damage endothelial ion transport function, triggering vasogenic edema (Wan et al., 2023). Therefore, regulating fluid metabolism and ion homeostasis may reduce the severity of post-stroke cerebral edema: for post-ischemic cerebral edema, the focus is on repairing the sodium-potassium pump and regulating the expression and distribution of aquaporin AQP4; for post-hemorrhagic cerebral edema, the emphasis is on clearing toxic substances and restoring endothelial channel function. Regulating the expression and distribution of AQP4 is a hypothesized key mechanism for reducing astrocyte swelling and stabilizing BBB integrity. Preclinical studies suggest that several TCM interventions may act through this pathway. For instance, experimental models indicate that Tongxinluo Capsule can downregulate AQP4 expression, reduce T2WI relative signal intensity, and decrease brain water content (Cai et al., 2016). Similarly, the classic formula Wuling Powder has been shown in mice to reduce brain water content after ischemic stroke by suppressing AQP4, a mechanism that involves Mn2+ and Zn2+ ions and is consistent with its observed inhibition of AQP4-dependent permeability in MLE-12 cells (Nakano et al., 2018). In addition, emodin, a botanical metabolite exerts a protective effect on post-ischemic cerebral edema both in vivo and in vitro, inhibiting astrocyte swelling and BBB disruption mediated by AQP4 (Chen et al., 2024). Other botanical metabolites, such as cornel glycosides, which significantly reduced cerebral edema (p = 0.0018) (Wang et al., 2024b), and total steroid saponins, which also significantly reduced cerebral edema (p < 0.01) (Zhang et al., 2014), function through this pathway. Restoring ion pump function (enhancing Na+/K+-ATPase activity) and regulating ion channels (promoting intracellular Na+ and Ca2+ efflux) are core strategies for intervening in cytotoxic edema, aiming to maintain ion homeostasis in neurons and glial cells. The botanical metabolite gastrodin, for example, has been demonstrated in rat models to reduce excitotoxicity and oxidative damage by inhibiting glutamate release, blocking calcium overload, and reducing nitric oxide production, thereby decreasing infarct and edema volumes and improving neurological function (Zeng et al., 2006). Protecting and repairing the BBB Vasogenic edema is the main type of edema in intracerebral hemorrhage and the main form of edema transformation after cerebral ischemia-reperfusion, fundamentally resulting from disrupted BBB integrity, leading to extravasation of plasma components, especially protein-rich fluids, into the brain parenchyma. In the early stage of injury, activated endothelial cells and microglia/infiltrating inflammatory cells release matrix metalloproteinases MMP-9/MMP-2, which disrupt the BBB through a continuous three-level cascade (Lu and Wen, 2024): first, degrading key components of the basement membrane, such as laminin and type IV collagen; then, exposing adhesion receptors on the endothelial cell surface, promoting further adhesion and infiltration of inflammatory cells; finally, directly hydrolyzing tight junction proteins occludin, claudin-5, and ZO-1, leading to complete disintegration of anchoring structures between endothelial cells (Wang P. et al., 2022). Extravasated plasma components accumulate in the brain tissue interstitium to form vasogenic edema, and mechanically compress the local microcirculation system, exacerbating ischemic injury, thus forming a vicious cycle where edema aggravates ischemia and ischemia further exacerbates edema (Ng et al., 2022). Therefore, targeted inhibition of matrix metalloproteinase activity and promotion of tight junction protein network reconstruction are important intervention strategies to reduce cerebral edema and improve neurological prognosis. The key to repairing BBB tight junction structures lies in enhancing the expression, proper assembly, and localization of junction proteins (such as ZO-1, occludin, claudin-5). This is usually achieved by activating protective signaling pathways (such as HO-1, GSK-3β/β-catenin) or inhibiting destructive factors (such as caveolin-1) to reduce plasma leakage. For instance, Yiqi Fumai Powder Injection has been shown in mouse models to attenuate BBB leakage, upregulate the tight junction proteins ZO-1 and occludin (Cao et al., 2016). Similarly, Tongxinluo Capsule shares the same anti-edema mechanism in treating post-stroke cerebral edema (Liu et al., 2013). Naomao Granule alleviates BBB disruption and ischemic post-stroke cerebral edema by protecting tight junction proteins between cerebral microvascular endothelial cells, such as claudin-5, JAM-1, occludin, ZO-1, and inhibiting the expression of caveolin-1 (Huang et al., 2012). At the metabolite level, naringenin is proposed to upregulate tight junction proteins via the GSK-3β/β-catenin pathway (Yang et al., 2024), while curcumin (Wang et al., 2013) and baicalin (Zhu et al., 2012) have been reported to enhance junctional integrity, potentially through activating the HO-1 pathway. Inhibiting the expression and enzymatic activity of matrix metalloproteinases (MMPs, especially MMP-9 and MMP-2) is an effective mechanism to reduce vasogenic edema. This can be achieved by blocking their upstream activation signaling pathways (such as NF-κB, ERK1/2) or directly interfering with their synthesis and activation processes, effectively protecting the basement membrane and tight junction proteins from degradation. Preclinical studies indicate that crocin protects cortical microvascular endothelial cells from ultrastructural damage after cerebral ischemia-reperfusion. These protective effects are associated with the inhibition of ERK1/2 phosphorylation, blockade of GRK2 membrane translocation, and downregulation of MMP-9 expression, which collectively contribute to the reduction of oxidative stress and vasogenic edema, conferring multi-faceted protection (Zheng et al., 2007). Dihydrocaffeic acid, a metabolite of coffee components, has been reported to inhibit the expression and activation of MMP-2 and MMP-9, exerting a protective effect on ischemia-induced neuronal injury and cerebral edema (Lee et al., 2015). Ginsenoside Rd is proposed to reduce BBB injury and edema severity by inhibiting proteasome activity, reducing IκBα degradation, blocking NF-κB activation pathway, and downregulating MMP-9 expression (Zhang et al., 2020). Tetrahydro curcumin reduces MMP-9 activity and oxidative damage by inhibiting homocysteinylation of cytochrome c (Hcy-cyto-c), thereby alleviating BBB disruption and cerebral edema (Tyagi et al., 2012). Promoting angiogenesis and improving cerebral blood perfusion help alleviate ischemic injury and secondary edema. Houshi Heisan can promote angiogenesis through the HIF-1α/VEGF and SDF-1/CXCR4 pathways, relieve vascular edema, and reduce injury to blood vessels and neurons in the ischemic area (Xiang et al., 2019). Separately, studies suggest that the hexane extract of Uncaria rhynchophylla enhances endothelium-dependent vasodilation by activating the Akt/eNOS signaling pathway, improves perfusion in the ischemic penumbra, and may thereby contribute to the reduction of cerebral edema (Park et al., 2011). Inhibiting neuroinflammatory cascades Neuroinflammation is a key bridge connecting cytotoxic and vasogenic edema, amplifying both processes. In the acute phase of stroke, activated microglia, infiltrating neutrophils, and reactive astrocytes release various pro-edema mediators, including IL-1β, HMGB1, and MMPs (Chen et al., 2021; Wang X. et al., 2022). These factors exacerbate edema formation through multiple pathways: IL-1β and HMGB1 activate the endothelial cell NF-κB pathway, induce matrix metalloproteinase expression, and indirectly disrupt the integrity of BBB tight junction proteins; simultaneously activated complement cascades produce C3a/C5a, synergistically promoting leukocyte adhesion and inflammatory infiltration. Sustained inflammatory stimulation also disrupts the polar distribution of aquaporin AQP4, promoting the transformation of cytotoxic edema to vasogenic edema (Zheng et al., 2025). It should be noted that pro-inflammatory mediators released by reactive astrocytes in the early stage exacerbate injury, but they also participate in protection in the later stage by secreting neurotrophic factors and barrier repair proteins. Therefore, early targeted intervention in the neuroinflammatory cascade can effectively reduce cerebral edema and improve neurological prognosis. Targeting the TLR4/NF-κB signaling pathway represents a promising strategy to reduce neuroinflammation and cerebral edema, as this pathway is activated by DAMPs to drive pro-inflammatory factor expression. Similarly, inhibition of the NLRP3 inflammasome and its upstream signals (e.g., CaMKII/NF-κB) may effectively block inflammatory cascade amplification, thereby reducing BBB injury (Cai et al., 2016). Zhongfeng Xingnao Decoction was shown to reduce inflammatory responses and the volume of perihematomal edema by regulating the activation of NLRP3 inflammasome after intracerebral hemorrhage, which is related to the CaMKII/NF-κB p65/NLRP3/GSDMD signaling axis (Yu et al., 2025). Pretreatment with Qishen Yiqi Formula in mouse models inhibited neuroinflammatory responses, protected the BBB, and reduced cerebral edema, which significantly attenuated midline shift caused by brain swelling (p < 0.001), concomitant with downregulation of IFNG-γ, IL-6, TNF-α, NF-κB p65, and TLR-4 mRNA (Wang et al., 2020). Network pharmacological analysis shows that Miaoyao Xuemaitong Capsule can alleviate intracerebral hemorrhage-induced inflammation and edema by regulating the TNFR1/NF-κB and TNFR1/MAPK signaling pathways (Zhang et al., 2021). In addition, the botanical metabolite verbenalin reduces acute inflammatory injury and cerebral edema in intracerebral hemorrhage by inhibiting TLR4 (Lai et al., 2019). Both jolkinolide B (Ma et al., 2024) and ginkgolide B (Chen et al., 2018) improve hypoxic-ischemic brain injury in newborn male rats by inhibiting NLRP3 inflammasome activation, alleviating cerebral edema. Ginkgolide C (Li et al., 2023) reduces inflammation-induced injury caused by cerebral ischemia/reperfusion by inhibiting the CD40/NF-κB pathway, improves microvascular ultrastructural characteristics, and ameliorates BBB disruption, thereby reducing cerebral edema. Regulating the MAPK signaling pathway (such as JNK, p38) is an important approach to intervene in inflammatory mediator release and BBB disruption. Experimental studies suggest that leonurine can reduce BBB disruption in vivo by inhibiting hemoglobin degradation and inflammatory mediator release, a process associated with the JNK signaling pathway and the inhibition of oxyhemoglobin-induced inflammatory protein expression in BV-2 cells (Lin et al., 2016). Similarly, proanthocyanidins have been shown in rat models to exert neuroprotective effects against cerebral ischemia, which are correlated with the inhibition of the TLR4-p38-NF-κB-NLRP3 signaling pathway and a reduction in cerebral edema (Yang et al., 2020). Modulating the activity of microglia and astrocytes offers a broader anti-inflammatory approach. The combination of jolkinolide B and ginsenoside Rg1 has been reported to reduce neuroinflammation and cerebral edema in experimental models, potentially by inhibiting miR-155-5p expression in microglia (Wang et al., 2018). Ginkgo diterpene lactones can alleviate OGD/R injury in primary astrocytes and LPS-induced inflammatory responses, reducing infarct volume and cerebral edema (Li X. et al., 2020). Methanol extracts of Glycyrrhiza uralensis and its roots regulate inflammation-related neuronal cells such as microglia and astrocytes, thereby reducing edema volume and exerting neuroprotective effects on ischemic stroke (Choi et al., 2022). Other botanical metabolite such as tetramethylpyrazine (Liao et al., 2004), paeonol (Zhao et al., 2018), and furanocoumarin dimers (Mi et al., 2021) also function through this mechanism. Other pathways, such as artemisinin, can upregulate the expression of neural cell adhesion molecule L1, inhibit inflammation and oxidative stress, and alleviate cerebral edema (Wang X. et al., 2022). Anti-oxidative stress After ischemic or hemorrhagic stroke, excessive production of reactive oxygen species and reactive nitrogen species triggers cascading oxidative damage, leading to lipid peroxidation of vascular endothelial cell membranes (Kim et al., 2021), and inducing nitration or carbonylation of key structural proteins such as tight junction proteins, thereby disrupting BBB integrity, increasing microvascular permeability, and ultimately promoting the formation of vasogenic edema (Chen S. et al., 2022). In addition, mitochondrial oxidative stress can further exacerbate neuronal apoptosis and cytotoxic edema (Panickar and Anderson, 2011). Therefore, anti-oxidative stress can indirectly exert anti-edema effects on post-stroke cerebral edema by repairing the BBB. Activating the Nrf2/HO-1 signaling pathway is a core cellular anti-oxidative defense mechanism. Preclinical studies indicate that several TCM interventions may confer protection by enhancing the activity of endogenous antioxidant enzymes and decreasing levels of lipid peroxides. For instance, Multiple studies have demonstrated that Dracocephalum moldavica (Jia et al., 2017), lavender oil (Vakili et al., 2014), Houttuynia cordata, and the botanical metabolite oleanolic acid (Cho et al., 2009) can enhance endogenous antioxidant defense, inhibit oxidative stress, and thus reduce cerebral edema by decreasing malondialdehyde content and increasing the activities of superoxide dismutase and glutathione peroxidase. Among them, lavender oil also exerts synergistic effects by increasing VEGF expression. Intranasal administration of catalpol upregulates the expression of Nrf2 and HO-1 to reduce oxidative stress injury, increase SOD activity, decrease MDA activity, and reduce infarct volume, neurological dysfunction, and cerebral edema (Wang P. et al., 2022) The botanical metabolite astragaloside IV (Zhang et al., 2023), dendrobium nobile glycoside (Qiao et al., 2023), and soy isoflavones (Xue et al., 2025) also function through this signaling pathway. In addition, apigenin can promote DNA repair by inhibiting the PARP1/AIF pathway, reduce ROS and malondialdehyde, increase glutathione and superoxide dismutase, improve antioxidant capacity, thereby reducing infarct volume and neurological deficits, decreasing edema volume, and reducing blebbing and cell death (Ping et al., 2024). Direct scavenging of harmful reactive nitrogen species or inhibiting their key generating enzymes can specifically reduce oxidative damage such as protein nitration, thereby alleviating cerebral edema. Hydroxysafflor yellow A reduces protein tyrosine nitration by directly scavenging peroxynitrite and inhibiting the expression of inducible nitric oxide synthase (iNOS), thereby reducing post-ischemic cerebral edema (Sun et al., 2013). Anti-apoptosis In cerebral ischemia-reperfusion injury, activation of the neuronal apoptotic pathway exacerbates cerebral edema through dual mechanisms: caspase activation driven by the mitochondrial pathway leads to caspase-3-mediated cleavage of the Na+/K+-ATPase α subunit, directly di (Cheng et al., 2020; Panickar and Anderson, 2011)srupting ion homeostasis and worsening cytotoxic edema. Meanwhile, damage-associated molecular patterns released by apoptotic neurons activate microglia, triggering cascading release of pro-inflammatory factors such as TNF-α and IL-1β, which further degrade tight junction proteins and induce vasogenic edema (Sadeghian et al., 2019). Targeting upstream apoptotic signal hubs (PI3K/AKT, MAPK) can inhibit apoptosis. Experimental evidence suggests that Shilong Qingxue Granule (SQG) alleviates glutamate-induced neuronal calcium overload, ROS accumulation, and mitochondrial damage by inhibiting the mitochondrial apoptotic pathway and regulating the MAPK signaling pathway, thereby relieving cytotoxic edema (Hu et al., 2025). Schisandrin reduces apoptosis, inflammatory responses, and oxidative stress in MCAO rats by regulating the PI3K/AKT pathway, preventing ischemic brain injury and reducing brain water content (Hong et al., 2023). Ginkgolide B has been shown in vivo and in vitro to inhibit apoptosis by activating the PI3K/Akt pathway, suggesting a neuroprotective effect against cerebral ischemia/reperfusion injury that includes a reduction in cerebral edema (Khadankhuu et al., 2021). Inhibiting apoptosis can be achieved by intervening in related processes such as autophagy and energy metabolism. Excessive autophagy can induce apoptotic death, and energy failure directly activates apoptosis, both of which are closely coupled with apoptosis. Danhong Injection has been demonstrated in rat models to alleviate cerebral edema and rescue neuronal injury in the ischemic penumbra. This effect is proposed to involve the regulation of intracellular energy metabolism—namely, restoring cytoplasmic glycolytic activity and relieving mitochondrial metabolic inhibition—potentially through inhibiting the activation of the PARP1/AIF and HIF1α/PDK1 signaling pathways (Zeng et al., 2021). Arctigenin improves cerebral ischemia by inhibiting neuronal apoptosis and AMPK/mTOR-mediated autophagy, reducing cerebral edema and improving neurological function scores (Yang et al., 2021). Other potential mechanisms Focusing on metabolic homeostasis repair, regulating key metabolic pathways such as membrane components and energy metabolism can reduce glial cell edema. A study using metabolomics demonstrated that Longxue Tongluo Capsule can normalize metabolic disorders and reduce neuroglial interstitial edema by regulating metabolic pathways involving glycerophospholipid metabolism, glycosylphosphatidylinositol anchor biosynthesis, nicotinate and nicotinamide metabolism, and sphingolipid metabolism (Sun et al., 2023). Improving cerebral microcirculation, anti-platelet aggregation, and anti-thrombosis can reduce neuronal necrosis and glial cell edema caused by ischemia. Supercritical CO2 extract of Salvia miltiorrhiza (SCED) improves microcirculation by inhibiting platelet PLC/PKC signaling pathway activation, blocking thromboxane A2 release, and inhibiting platelet aggregation, thereby improving cerebral blood perfusion and reducing cerebral ischemic injury and edema (Fei et al., 2017). Current limitations and future perspectives Defects in clinical trial design Although multiple clinical studies have demonstrated the improvement effect of Chinese botanical drug preparations, Chinese botanical drug, and their metabolites on post-stroke cerebral edema, there remains a problem of insufficient sample size. Moreover, the included clinical studies exhibited certain heterogeneity in experimental design, with some lacking detailed double-blind procedures, which may increase the risk of bias. Some studies did not perform formal sample size calculations or power analyses, potentially limiting the statistical reliability of their findings. Furthermore, most available publications tend to report positive or favorable outcomes, while studies with negative or inconclusive findings are rarely accessible, particularly within Chinese-language databases. This publication and selection bias may lead to an overestimation of the therapeutic efficacy of Chinese botanical drugs. Another critical issue identified in the reviewed clinical trials is the lack of standardized safety reporting. Adverse event reporting is often inconsistent or inadequately detailed, which hinders the comprehensive assessment of the safety profile of Chinese botanical drugs in clinical settings. This gap in safety reporting, combined with the aforementioned methodological issues, further diminishes the overall reliability of the evidence. Future investigations should prioritize well-designed randomized controlled trials (RCTs) with adequate sample sizes and standardized outcome measures to enhance the robustness and reproducibility of clinical evidence. In particular, studies should adhere to rigorous adverse event reporting standards to ensure comprehensive safety evaluation. In addition, the differential effects of TCM in different stages of cerebral edema, i.e., the acute phase (0–72 h) and the recovery phase (7–14 days), need further exploration. Insufficient translation from basic research to clinical practice Basic studies have revealed multiple mechanisms through which TCM may alleviate post-stroke cerebral edema. However, despite these mechanistic advances, effective clinical translation remains limited. Many preclinical findings have not been systematically verified in humans, leading to uncertainties in dose–response relationships, pharmacodynamic stability, and safety under complex clinical conditions (Li et al., 2022; Sun et al., 2019). Key barriers include inconsistent dose conversion between animal and human studies, variability in pharmacokinetics among multi-component botanical formulations, and the absence of unified regulatory and quality-assessment frameworks. Furthermore, poor bioavailability and limited blood–brain barrier permeability of metabolites often compromise therapeutic efficacy (Sanchez-Martinez et al., 2022). Future research should prioritize dose optimization, formulation improvement to enhance bioavailability, and pharmacokinetic–pharmacodynamic modeling (Dewi et al., 2022; Xie et al., 2025). Integrating TCM-based evidence into standardized and evidence-based evaluation systems will be essential to improve credibility and facilitate clinical adoption (Li R. et al., 2024). Difficulties in analyzing components of Chinese medicines In basic research, TCM, especially botanical formulas, has extremely complex compositions: a single Chinese medicinal material may contain dozens to hundreds of active metabolites, while formulas are combinations of multiple medicinal materials, leading to superimposed metabolites. This complexity enables them to exert therapeutic effects through multiple mechanisms, but precise analysis of specific molecular targets is challenging. The optimal effective doses and proportions of different active components in compound formulas, as well as the pathways through which different components synergistically function, require in-depth research. Challenges in quality control of botanical drug Contamination and adulteration of TCM raw materials can cause severe adverse reactions. A systematic review including 26 cases of botanical drug contamination and adulteration pointed out that the most common herbal contaminants include dust, pollen, insects, rodents, parasites, microorganisms, fungi, molds, toxins, pesticides, and toxic heavy metals. Adulteration and contamination can cause severe adverse reactions such as arsenic, lead, or mercury poisoning, hepatorenal syndrome, nephrotoxicity, metabolic acidosis, renal or liver failure, cerebral edema, and coma (Posadzki et al., 2013). Contamination and adulteration of TCM are core issues threatening medication safety, which need to be addressed through multiple dimensions such as technological innovation, strengthened supervision, and international cooperation to unify standards. In recent years, several pharmacopeial and international standards have been established to improve quality assurance in botanical drug production. The Chinese Pharmacopoeia (2020 Edition) and WHO Monographs on Selected Medicinal Plants specify detailed requirements for botanical identification, permissible levels of heavy metals, pesticide residues, and microbial contamination (Leong et al., 2020). In parallel, modern analytical techniques such as high-performance liquid chromatography, liquid chromatography–mass spectrometry, gas chromatography, and emerging molecular tools like DNA barcoding and metabarcoding have greatly improved the accuracy of species authentication and detection of adulterants (Bogusz et al., 2006; Techen et al., 2014). Integration of these pharmacopeial standards and analytical methods provides a practical and effective framework for ensuring the safety, consistency, and authenticity of TCM products (Wang et al., 2023). Future research should focus on the toxic mechanisms and risk thresholds of contaminants to provide a basis for formulating scientific limit standards. Conclusion This review has synthesized evidence on the efficacy, safety, and potential mechanisms of selected TCM interventions for post-stroke cerebral edema. Clinical evidence, primarily from preliminary studies, suggests that specific TCM formulations can reduce cerebral edema volume and improve neurological function with a generally acceptable safety profile. The preclinical findings summarized herein indicate that these benefits may be mediated by multi-target effects, including the regulation of ion homeostasis and aquaporins, inhibition of neuroinflammatory cascades, protection of the blood-brain barrier, and mitigation of oxidative stress and apoptosis. While osmotic agents and surgery remain the standard of care, the profiled TCM interventions hold promise as adjunctive therapies due to their potential to simultaneously target multiple interconnected pathways in the edema pathological network. However, this very complexity necessitates future research that prioritizes rigorous, large-scale clinical trials to confirm efficacy, standardized safety monitoring, and mechanistic studies to establish causal relationships in humans and identify the key active constituents. Overcoming these challenges will be crucial to translate these promising preclinical findings into validated therapeutic strategies.